Trial Details

Authorised
Basic Information
Clinical ID c2707
Identifier EUCTR2018-002925-47-ES
Trial Title Identification of predictive biomarkers for response to biologic therapies in inflammatory bowel disease by proteomic and mass cytometry approaches
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflammatory bowel disease _ MedDRA version: 20.1_ Level: LLT_ Classification code 10045365_ Term: Ulcerative colitis_ System Organ Class: 10017947 - Gastrointestinal disorders_ _ MedDRA version: 20.0_ Level: PT_ Classification code 10011401_ Term: Crohn's disease_ System Organ Class: 10017947 - Gastrointestinal disorders_ ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Interventions Trade Name: Adalimumab Pharmaceutical Form: Injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Infliximab Pharmaceutical Form: Infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 5- Trade Name: Golimumab Pharmaceutical Form: Injection INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Ustekinumab Pharmaceutical Form: Injection INN or Proposed INN: USTEKINUMAB CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Trade Name: Vedolizumab Pharmaceutical Form: Infusion INN or Proposed INN: VEDOLIZUMAB CAS Number: 943609-66-3 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-
Participant Information
Sponsor Fundacin de Investigacin Biomica del Hospital Universitario de La Princesa
City -
Country/Region Spain
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE4
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -